Clinical Research

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

The primary study hypotheses are:

1. SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution), and
2. SBRT plus pembrolizumab prolongs Overall Survival (OS) compared to SBRT plus placebo.

I Want to Participate

Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician. 

View Trial

For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:

• Your name
• Phone number & if we can leave a voice message at this number
• Trial number(s) you are interested in
• Name and city of clinic you are currently being treated